Ascelia Pharma has issued a Q2 2026 update following a setback involving its lead candidate Orviglance. The update follows an FDA meeting that will be key to the next steps for the program.
Further verified details were not immediately available.
Ascelia Pharma Q2 2026 update follows Orviglance setback
The company’s second-quarter 2026 update follows a recent setback for its lead candidate Orviglance.
PA
Priya Anand · Equities & Earnings Desk · 21 Aug 2026 · 09:25 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
